Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...

GeoVax’s development-stage continuous avian cell line process is anticipated to provide increased production of MVA-based vaccines, the ability to quickly respond to epidemics and pandemics ...

GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.

View the latest GeoVax Labs Inc. Wt (GOVXW) stock price, news, historical charts, analyst ratings and financial information from WSJ.

ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...

GeoVax's intellectual property estate now encompasses over 135 granted or pending patent applications across 23 distinct patent families, reinforcing the company's strategic position across ...